Document Detail

The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor.
MedLine Citation:
PMID:  23615159     Owner:  NLM     Status:  Publisher    
: Edoxaban is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention in patients with atrial fibrillation, an elderly population that frequently receives aspirin (ASA) and/or nonsteroidal anti-inflammatory drugs for concurrent illnesses. Three studies were conducted to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) interactions of edoxaban 60 mg coadministered with low-dose (100 mg) ASA, high-dose (325 mg) ASA, or naproxen (500 mg) in healthy subjects (N=126). Template bleeding times (BT) were measured. Mean baseline (predose) BT for the 3 studies ranged from 4.72 to 6.13 minutes. Edoxaban administered alone increased BT by 21% to 35% (4 hours postdose) from baseline. Concomitant administration of edoxaban with high-dose ASA, low-dose ASA, or naproxen increased BT approximately 2-fold showed an additive effect of either agent administered alone. Edoxaban PK was not affected by concomitant low-dose ASA or naproxen, but high-dose ASA increased systemic exposure of edoxaban by approximately 30%. The effects of edoxaban on prothrombin time, activated partial thromboplastin time, international normalized ratio, anti-FXa, and intrinsic FXa activity were not influenced by administration with ASA or naproxen. Inhibition of platelet aggregation by high-dose ASA, low-dose ASA, or naproxen was not affected by edoxaban. Concomitant administration of edoxaban and ASA or naproxen was well tolerated.
Jeanne Mendell; Frank Lee; Shuquan Chen; Valerie Worland; Minggao Shi; Meyer Michel Samama
Related Documents :
109099 - Des 4-trans-hydroxy-glibenclamide show hypoglycemic activity?
2175139 - Inhibition by dexamethasone of arginine vasopressin and acth responses to insulin-induc...
16154499 - Effects of different fungal elicitors on growth, total carotenoids and astaxanthin form...
24022709 - Pharmacokinetic interaction studies of fenugreek with cyp3a substrates cyclosporine and...
23853649 - Role of benzodiazepines in the management of agitation due to inappropriate use of nalt...
9580619 - Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10h)-...
23669879 - Neuromuscular responses to incremental caffeine doses: performance and side effects.
23150739 - In vivo study on the pharmacological interactions between a chinese herbal formula elp ...
2890149 - Famotidine pharmacokinetics following oral and intravenous administration in patients w...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-4-23
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  -     ISSN:  1533-4023     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-4-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
*Daiichi Sankyo Pharma Development, Edison, New Jersey; †Celerion, Inc., Neptune, New Jersey; ‡L'hopital Hotel-Dieu, Paris, France, and Biomnis Laboratory, Ivry-sur-Seine, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Atorvastatin inhibits the 5-Lipoxygenase pathway and expression of CCL3 to alleviate atherosclerotic...
Next Document:  Alike but not the same: anatomic heterogeneity of estrogen receptor-mediated vasodilation.